Helping patients find the non-small cell lung cancer
resources they deserve
How do we help non-small cell lung cancer patients?
Massive Bio offers an independent cancer treatment analysis as well as free clinical trial matching for non-small cell lung cancer patients. Our patient advocates work closely with patients to gather information on their current medical status, and then will provide a list of options from available cancer clinical trials close to your home.
We can also provide a comprehensive case analysis through our Virtual Tumor Board from cancer specialists. The Virtual Tumor Board (VTB) is comprised of highly specialized oncologists from nationally-recognized Cancer Centers of Excellence. In just 7-10 days after receiving your medical records, we can get you a treatment plan without having to travel far distances and use your valuable time.
There are approximately 835 clinical trials for non-small cell lung cancer patients recruiting patients in the United States. With such a long list of trials, it is difficult to know which one is the most beneficial for you. Our team of patient advocates, case managers, and our artificial intelligence based clinical trial matching system will find the best option for your individual case.
With just a few clicks, you can see your clinical trial matches now. Click here to use our advanced clinical trial match tool.
What is Non-Small Cell Lung Cancer?
Non–small cell lung cancer accounts for 85% of all lung cancer cases in the United States. NSCLC is the most common form of lung cancer and is a general term for several different types of cancer in the lungs including:
- Squamous cell carcinoma
- Large cell carcinoma
- Other rare types
Lung cancer is characterized by small cell and non-small cell. Small cell lung cancer is the less common type of lung cancer, but it spreads faster than NSCLC. Small cell cancer cells under a microscope appear small and round compared to non-small cells. An overwhelming majority of small cell lung cancer patients have a history of smoking.
Non-Small Cell Lung Cancer Facts
Lung cancer is the leading cause of cancer-related mortality, not only in the United States but also around the world. Early lung cancer screenings can detect Lung cancer is the number one cause of cancer death in the United States, estimated to cause 158,000 deaths in 2016, and accounting for 26.5% of all cancer deaths. Close to 70% of patients with NSCLC are diagnosed with locally advanced or metastatic disease at the time of diagnosis, which limits the available treatment options. There will be an estimated 240,000 total cases of lung cancer in 2020, with slightly more cases occurring in men than women. The current estimated 5-year survival rate is 15% for NSCLC patients.
Non-Small Cell Lung Cancer Treatments
The treatment options for NSCLC patients often includes:
- Radiation therapy
Radical surgery is the standard of care for fit, stage I NSCLC patients. Chemotherapy is used with concurrent radiation for some locally advanced cancers, and palliative chemotherapy for metastatic disease to relieve symptoms and improve quality of life.
Immunotherapy has revolutionized the landscape of NSCLC targeted treatments, significantly prolonging the overall survival of advanced stage patients. Immunotherapy drugs approved to treat lung cancer belong to a class of drugs called checkpoint inhibitors. Doctors use several targeted therapies to treat some advanced non-small cell lung cancers, either alone or along with chemotherapy.
Our patient advocates can help guide you to treatment options you might not have been previously aware of. Navigating cancer patients through the path of choosing the best treatment is our goal. No two cancer patients are alike, which is why we find treatment for every patient based on their individual cancer case including specific genomics, location, stage of cancer, and nearly 100 more data points.